Hong Kong Stocks Midday: Hang Seng Index Rises 0.84%, Tech Index Up 0.54%, Internet Tech Stocks Active, Application Software Sector Declines, Zhipu Falls Over 11%

Deep News12:11

Hong Kong's three major indices all rose collectively. As of the midday close, the Hang Seng Index gained 0.84% to 23,835.44, the Hang Seng Tech Index rose 0.54%, and the State-owned Enterprises Index advanced 0.8%.

On the board, internet tech stocks were mixed with more gainers than losers. Meituan rose over 3%, Baidu gained more than 2%, while Lenovo dropped over 4%; catering stocks led the gains, with Haidilao up more than 4%; the application software sector declined, with Zhipu falling over 11%; the biopharmaceutical sector broadly declined, with AKESO dropping more than 23%.

Catering stocks led the gains, with Haidilao rising over 4%. Data from the National Bureau of Statistics shows that from January to September this year, catering revenue reached 419.69 billion yuan, up 2.4%, leading the broader market by approximately 1.4 percentage points. Northeast Securities pointed out that after the retreat of food delivery subsidies, the industry generally faces high base pressure, and the same-store data of leading groups demonstrates resilience. After half a year of valuation digestion, both sector valuations and market expectations are currently at absolute lows, and attention should be paid to industry leaders with endogenous growth engines and deep moats.

The application software sector declined, with Zhipu falling over 11%. Nvidia founder Jensen Huang's departure continues to stir the AI industry chain. A research report from Zhongtai International pointed out that the "core trigger of this round of tech stock adjustment comes from overseas," and the volatility brought by Jensen Huang's departure to the AI sector is expected to continue.

The biopharmaceutical sector broadly declined, with AKESO dropping more than 23%. On Sunday local time, Miami-based American biotech company Summit Therapeutics stated that the U.S. FDA has refused to approve its anticancer drug Ivonescimab. The drug was originally developed by AKESO in Zhongshan, China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment